Sunshine Biopharma Inc
NASDAQ:SBFM

  • LAST PRICE
    2.4400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.3600/ 5
  • Ask / Lots
    2.5200/ 3
  • Open / Previous Close
    --- / 2.4400
  • Day Range
    ---
  • 52 Week Range
    2.1056
    637.2000
  • Volume
    25

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
SBFM
Sunshine Biopharma Inc
4.7M
0.0x
---
YCBD
cbdMD Inc
1.7M
0.0x
---
CYAN
Cyanotech Corp
2.7M
-0.4x
---
GLSHQ
Gelesis Holdings Inc
70.0
0.0x
---
SYVC
Synovics Pharmaceuticals Inc
3.0K
0.0x
---
NTII
Neurobiological Technologies Inc
2.7K
0.0x
---
As of 2024-11-26

Company Information

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Contact Information

Headquarters
333 Las Olas Way, Cu4 Suite 433FORT LAUDERDALE, FL, United States 33301
Phone
954-515-0810
Fax
514-426-6101

Executives

Chairman of the Board, President, Chief Executive Officer
Steve Slilaty
Chief Financial Officer, Secretary
Camille Sebaaly
Chief Operating Officer
Marc Beaudoin
Chief Science Officer, Director
Abderrazzak Merzouki
Chief Development Officer
Malek Chamoun

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$4.7M
Revenue (TTM)
$33.0M
Shares Outstanding
2.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.00
EPS
$-144.23
Book Value
$1,513.73
P/E Ratio
0.0x
Price/Sales (TTM)
0.1
Price/Cash Flow (TTM)
---
Operating Margin
-15.05%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.